‘Sometimes I don’t even take my medicine’: Americans are choosing between insulin and buying gas following Trump’s ACA cuts

About 8 in 10 ACA marketplace enrollees who re‑enrolled report higher health costs after the Dec. 31 expiration of enhanced tax credits, leaving roughly 23 million enrollees exposed to higher premiums. In a KFF follow‑up poll of 1,117 2025 marketplace enrollees (±3.8pp), ~55% said they plan to cut spending on food/basic needs, ~10% dropped coverage, and many downgraded plans as premiums jumped (examples: a mid‑tier plan near‑tripled to ~$1,200/month; another $500/month premium was set to double). The unresolved congressional fight over restoring subsidies is driving acute anxiety about emergency and routine care and is worsening affordability rather than creating immediate market price moves.

Analysis

The abrupt removal of broad premium subsidies creates a two-layered dislocation: immediate consumer price sensitivity raising demand for lower-cost generics and retail pharmacy substitutes, and a medium-term insurance pool reconfiguration that magnifies adverse selection. Expect utilization patterns to shift — deferred elective care and routine management (diabetes, hypertension) compress near-term revenue for hospitals and specialty providers, while increasing future acuity and uncompensated care burdens on safety-net systems over 6–18 months.

Politically driven policy risk is the dominant catalyst; a targeted subsidy restart or drug-pricing diktat could swing market expectations quickly within a 1–6 month window around legislative action or campaign-season bargaining. Conversely, absent relief, state-level insurance markets will see premium volatility and plan exits that force insurers to reprice or push for federal backstops, creating binary moves in health insurers and PBMs tied to perceived regulatory exposure.

Second-order winners and losers are non-obvious: big-box retailers and mail-order/discount pharmacies are positioned to capture share as cash-strapped patients prioritize out-of-pocket price, while insulin and specialty-biotech names face concentrated political and legal risk that is underpriced in near-term options markets. The path to normalization is neither linear nor quick — expect episodic relief rallies and decays as headlines around subsidy negotiations, midterm electoral positioning, and targeted drug-price proposals punctuate the next 3–12 months.

Key Decisions for Investors

• Long WMT (Walmart) 3–12 months: buy shares or a 6–12 month call diagonal to leverage steady upside from increased low-cost pharmacy and essential retail demand. Risk: margin pressure from broader consumer slowdown; Reward: 15–25% relative upside if retail share gains accelerate and pharmacy volumes rise.
• Pair trade — Long CVS Health (CVS) / Short UnitedHealth (UNH) 1–6 months: go +2% notional CVS / -2% UNH (or use equal-dollar options) to capture retail/PBM resilience vs. ACA risk sensitivity at diversified insurers. Risk: idiosyncratic execution (CVS integration) or UNH outperformance; Reward: targeted 10–20% relative move if subsidy headlines increase PBM transactional volumes while insurers face enrollment churn.
• Buy 6–18 month out-of-the-money puts on major insulin/specialty pharma (e.g., LLY, NVO) sized as a policy hedge: protect portfolio against legislative price caps or negotiation expansions. Risk: premiums decay if no policy action; Reward: >3x payoff on a regulatory shock that compresses specialty pricing multiples.
• Long Molina Healthcare (MOH) 6–12 months: accumulate on weakness to play Medicaid and low-income enrollment flow if market segmentation increases; consider 9–12 month calls to amplify. Risk: state budget squeezes and capitation pressure; Reward: 20–40% upside if enrollment shifts into Medicaid-managed care accelerate.